1. Scrip
  2. >>Business

Remsima Stars In Orion Pharma’s First Half

 
• By John Davis

Sales in Scandinavia of the biosimilar infliximab drove Orion’s specialty business in the first six months of 2016.

Orion
The Orion Constellation

The biosimilar Remsima (infliximab), a generic version of Johnson & Johnson/Merck & Co. Inc.’s Remicade, became the fifth best-selling product for Finland’s Orion Pharma during the first half of 2016, achieving sales of €22m (+161%) and accounting for 4% of Orion’s sales revenues of €535m in the half.

“Orion continued to enjoy winning some tenders here in Scandinavia, where we sell the product,” commented company CEO Timo Lappalainen...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.